Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: A 24-month prospective randomised clinical study

British Journal of Ophthalmology

Volumn 96, Issue 5, 2012, Pages 714-718

  Söderberg, Anne Catherine ^a   Algvere, Peep V ^a   Hengstler, Jürg C ^a   Söderberg, Pär ^b   Seregard, Stefan ^a   Kvanta, Anders ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE; FUSIDIC ACID; RANIBIZUMAB;

ARTICLE; BIOMICROSCOPY; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORNEA LIMBUS; DOUBLE BLIND PROCEDURE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SLIT LAMP; SUBRETINAL NEOVASCULARIZATION; TRANSPUPILLARY THERMOTHERAPY; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; HYPERTHERMIA, INDUCED; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; PUPIL; RETINA; RETREATMENT; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84860224470     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300721     Document Type: Article

References (19)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
2. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
3. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology 2011;118:831-9.
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
5. Martin DF, Maguire MG, Ying GS, et al; CATT Research group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
6. Algvere PV, Libert C, Lindgärde G, et al. Transpupillary thermotherapy of predominantly occult choroidal neovascularization in age-related macular degeneration with 12 months follow-up. Acta Ophthalmol Scand 2003;81:110-17. (Pubitemid 36609210)
7. Lanzetta P, Michieletto P, Pirracchio A, et al. Early vascular changes induced by transpupillary thermotherapy of choroidal neovascularisation. Ophthalmology 2002;109:1098-104. (Pubitemid 34546917)
8. Mainster MA, Reichel E. Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis and heat shock proteins. Ophthalmic Surg Lasers 2000;31:359-73.
9. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularisation in patients with age-related macular degeneration. Ophthalmology 1999;106:1908-14.
10. Odergren A, Algvere PV, Seregard S, et al. A prospective study on transpupillary thermotherapy (TTT) versus photodynamic therapy (PDT) for neovascular age-related macular degeneration. Br J Ophthalmol 2008;92:757-61. (Pubitemid 351850187)
11. Ming Y, Algvere PV, Odergren A, et al. Subthreshold transpupillary thermotherapy reduces experimental choroidal neovascularisation in the mouse without collateral damage to the neural retina. Invest Ophthalmol Vis Sci 2004;45:1969-74. (Pubitemid 38868996)
12. Odergren A, Ming Y, Kvanta A. Photodynamic therapy of experimental choroidal neovascularization in the mouse. Curr Eye Res 2006;31:765-74. (Pubitemid 44373548)
13. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 2007;245:1273-80. (Pubitemid 47278663)
14. Kumar A, Gopalakrishnan K, Sinha S. Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population. Retina 2008;28:1132-7.
15. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85. (Pubitemid 46829388)
16. Vallance JH, Johnson B, Majid MA, et al. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24:1561-7.
17. Odergren A, Algvere PV, Seregard S, et al. Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. Acta Ophthalmol 2010;88:426-30.
18. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43-58.
19. Holz FG, Amuako W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study. Ophthalmology 2011;118:663-71.